Retatrutide (LY3437943) is a triple GIP/GLP-1/glucagon receptor agonist currently in Phase 3 clinical trials. This page summarizes the dose-escalation schedules and adverse-event rates reported in published clinical trials, provided as a research reference only.
Retatrutide represents the next generation of incretin-based peptides. Unlike semaglutide (GLP-1 agonist) or tirzepatide (dual GLP-1/GIP agonist), retatrutide activates three metabolic pathways simultaneously:
In the SURMOUNT-1 trial (Jastreboff et al., 2023), participants achieved an average of 24.2% body weight reduction at the 12mg dose over 48 weeks—significantly higher than tirzepatide (20.9%) or semaglutide (17.4%).
The SURMOUNT trials used a gradual dose escalation protocol to minimize gastrointestinal side effects:
| Weeks | Dose (mg/week) | Purpose |
|---|---|---|
| 1-4 | 0.5 mg | Adaptation phase |
| 5-8 | 1 mg | Low reference dose |
| 9-12 | 2 mg | Moderate dose |
| 13-16 | 4 mg | Standard dose |
| 17-20 | 8 mg | High dose |
| 21+ | 12 mg | Maximum dose |
The published trials used the gradual dose-escalation schedule shown above to reduce gastrointestinal adverse events in study subjects. The figures below are drawn from the trial literature and describe the study cohorts — they are not projections for any individual purchaser.
In the Phase 2 trial (Jastreboff et al., 2023), mean body-weight reduction among study subjects increased with dose, reaching 24.2% at the 12 mg dose over 48 weeks. Appetite suppression and gastrointestinal effects were reported most frequently during the escalation phase and were dose-dependent. Retatrutide was administered by subcutaneous injection once weekly to trial subjects under study protocols.
The most commonly reported adverse events across the retatrutide trials were gastrointestinal. Incidence rates below are as reported in the published trial data for study subjects:
| Adverse Event | Reported Frequency (trial subjects) |
|---|---|
| Nausea | 30-40% |
| Diarrhea | 15-20% |
| Constipation | 10-15% |
| Injection site reactions | 5-10% |
| Fatigue | 10-15% |
In the trials, gastrointestinal adverse events were generally most pronounced during dose escalation and diminished over time. Serious adverse events were uncommon across all dose cohorts.
Retatrutide is temperature-sensitive. In Bali's tropical climate:
For detailed storage protocols in humid climates, see our Tropical Climate Storage Guide.
BioRelix supplies retatrutide as lyophilized powder (10mg vials). To prepare a research solution:
Full reconstitution tutorial: How to Reconstitute Peptides.
BioRelix supplies pharmaceutical-grade retatrutide in Bali with:
Order Retatrutide: 5mg (Rp 1,900,000) · 10mg (Rp 2,800,000) · 30mg (Rp 7,500,000) | Contact: Telegram @biorelix
© 2026 BioRelix · Bali, Indonesia · For research use only · Not for human therapeutic use